EPCAM and breast cancer: This is the case for ipilimumab and tremelimumab; anti-CTLA-4 antibodies which are currently being tested in 14 active studies [232]; lirilumab, an anti-killer immunoglobulin-like receptor 2D (anti-KIR2D) that affects the activity of the immune NK-cells [233]; vofatamab, a promising anti-fibroblast growth factor receptor 3 (anti-FGFR3) which is a target commonly affected in BC [234]; catumaxomab, an anti-epithelial cell adhesion molecule (anti-Epcam) commonly expressed by ascites [235]; or panitumumab, an anti-epithelial growth factor receptor (anti-EGFR) [236].